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Abstract
In the period April–September 2005, an outbreak of Clostridium difﬁcile infection (CDI) due to PCR ribotype 027 occurred among 50
patients in a 341-bed community hospital in Harderwijk, The Netherlands. A retrospective case–control study was performed to iden-
tify risk factors speciﬁc for CDI, using a group of patients with CDI (n = 45), a group of randomly selected control patients without
diarrhoea (n = 90), and a group of patients with non-infectious diarrhoea (n = 109). Risk factors for CDI and for non-CDI diarrhoea
were identiﬁed using multiple logistic regression analysis. Independent risk factors for CDI were: age above 65 years (OR 2.6; 95% CI
1.0–5.7), duration of hospitalization (OR 1.04 per additional day; 95% CI 1.0–1.1), and antibiotic use (OR 12.5; 95% CI 3.2–48.1). Of
the antibiotics used, cephalosporins and ﬂuoroquinolones were identiﬁed as the major risk factors for development of CDI. The risk of
developing CDI was particularly high in people receiving a combination of a cephalosporin and a ﬂuoroquinolone (OR 57.5; 95% CI
6.8–483.6). The main factors affecting the risk of non-CDI diarrhoea were proton-pump inhibitors, immunosuppressive drugs, underlying
digestive system disease, previous surgery, and gastric tube feeding. The outbreak ended only after implementation of restricted use of
cephalosporins and a complete ban on ﬂuoroquinolones, in addition to general hygienic measures, cohorting of patients in a separate
ward, education of staff, and intensiﬁed environmental cleaning. The results of this study support the importance of appropriate antimi-
crobial stewardship in the control of hospital outbreaks with C. difﬁcile PCR ribotype 027.
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Introduction
Clostridium difﬁcile infection (CDI) is one of the most com-
mon hospital-acquired infections, and is a frequent cause of
morbidity and mortality among elderly hospitalized patients
[1]. Recent reports indicate an increasing occurrence and
severity of CDI [2–5]. This change in epidemiology and clini-
cal presentation can, to a certain extent, be explained by the
spread of a new, potentially more virulent isolate, referred
to as PCR ribotype 027/toxinotype III/pulsed-ﬁeld gel elec-
trophoresis type NAP1/REA group BI (027/III/NAP1/BI),
which has caused outbreaks in North America and Europe
[6–12].
The most important risk factor for CDI is prior antibiotic
use. Other risk factors are: increasing age, severe underlying
disease, prolonged duration of hospitalization, CDI pressure
(deﬁned as the sum of a patient’s daily exposure to patients
with CDI who share the same unit or ward divided by the
length of stay of the patient at risk [13,14]), gastrointestinal
surgery, and enteral tube feeding [15–19]. During the recent
outbreaks caused by C. difﬁcile PCR ribotype 027, several
new putative risk factors have been reported, e.g. the use of
proton-pump inhibitors [20–22], of non-steroidal anti-inﬂam-
matory drugs [22], and of ﬂuoroquinolones [23–25].
Given the high a priori chance of non-infectious diarrhoea
developing in hospitalized patients, it is often difﬁcult to
distinguish between risk factors speciﬁc for CDI and risk
factors for diarrhoea due to other causes in the setting of an
epidemic of CDI.
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To unravel the risk factors speciﬁc for CDI, we performed
a case–control study using a group of patients with CDI and
a group of patients with non-infectious diarrhoea, both diag-
nosed during an outbreak of C. difﬁcile PCR ribotype 027 in
a community hospital.
Materials and Methods
Study population and deﬁnition of CDI cases
This study was conducted during an epidemic of CDI caused
by C. difﬁcile PCR-ribotype 027 in St Jansdal Hospital, a 341-
bed community hospital in Harderwijk, The Netherlands.
CDI was deﬁned by the presence of diarrhoea (two or more
loose bowel movements per day) and a positive C. difﬁcile
toxin assay result from a stool sample. All faecal samples
were tested within 1–18 h after arrival at the laboratory,
using a rapid enzyme immunoassay (ImmunoCard Toxin
A and B (ICTAB); Meridian, Boxtel, The Netherlands).
In patients with diarrhoea and a negative rapid immunoassay
result, a second faecal sample was tested after 24–48 h.
When two tests gave negative results, CDI was considered
to be unlikely.
Characterization of C. difﬁcile isolates
Toxin-positive faecal samples were cultured for the presence
of C. difﬁcile, using non-selective and selective agar supple-
mented with cefoxitin, amphotericin B, and cycloserin
(CLO-medium; Biome´rieux), with and without ethanol shock
pretreatment. After incubation in an anaerobic environment
at 37C for 48 h, colonies of Gram-positive rods with sub-
terminal spores were tested for the production of L-proline
aminopeptidase and for the hydrolysis of esculine. All cul-
ture-positive strains isolated from faecal samples were identi-
ﬁed as C. difﬁcile using a PCR for the presence of the gluD
gene encoding the glutamate dehydrogenase speciﬁc for C. dif-
ﬁcile [9]. C. difﬁcile isolates were tested for the presence of
the tcdA and tcdB binary toxin genes and deletions in tcdC,
as described previously [9]. PCR ribotyping and toxinotyping
were performed as described previously [26,27]. For all iso-
lates, susceptibility to erythromycin, ciproﬂoxacin, clindamy-
cin and metronidazole was determined by Etest (AB Biodisk,
Solna, Sweden).
Case–control study
To identify risk factors speciﬁc for CDI, patients were
assigned to three different study groups during the peak of
the outbreak in St Jansdal Hospital (Table 1). Study group I
consisted of 45 patients diagnosed with CDI as described
above. Study group II consisted of 109 patients diagnosed
with non-CDI diarrhoea, i.e. patients with diarrhoea who
tested negative in the C. difﬁcile toxin assay of two faecal
samples collected at least 24 h apart.
Study group III consisted of 90 randomly selected control
patients without diarrhoea. Patients with non-CDI diarrhoea
(study group II) and control patients (study group III) were
randomly selected from among all patients residing at the
same time and in the same ward as the patient newly diag-
nosed with CDI.
A standardized questionnaire was used to collect clinical
and demographic data from hospital records. Data were col-
lected concerning each participant’s age and gender, time of
onset and duration of diarrhoea, duration of hospital stay,
TABLE 1. Baseline characteristics of participants in the case–
control study
Characteristic CDI Non-CDI Controls
n 45 109 90
Gender
Male 19 (42.2) 36 (33.0) 42 (46.7)
Female 26 (57.8) 73 (67.0) 48 (53.3)
Age, years
18–64 8 (17.8) 41 (37.7) 30 (33.3)
‡65 37 (82.2)* 68 (62.3) 60 (66.7)
Main comorbidity (ICD-10 classiﬁcation)
Neoplasm 12 (26.7) 28 (25.7) 23 (25.6)
Endocrine disease 16 (35.6) 30 (27.5) 18 (20.0)
Cardiovascular disease 28 (62.2)** 52 (47.7) 34 (37.8)
Respiratory system disease 16 (35.6)* 14 (12.8) 17 (18.9)
Digestive system disease 11 (24.4) 32 (29.4)* 14 (15.6)
Musculoskeletal disease 6 (13.3) 14 (12.8) 10 (11.1)
Genitourinary disease 13 (28.9) 22 (20.2) 20 (22.2)
Duration of stay in hospital
(prior to diarrhoea), in days:
median (range)
7 (0)77)* 4 (0)97) 4 (0)63)
Level of care
Intensive-care unit stay 9 (20.0) 19 (17.4) 8 (8.9)
Surgery 7 (15.6) 42 (38.5)** 20 (22.2)
Endoscopy prior to CDI 6 (13.3) 9 (8.3) 11 (12.2)
Nasogastric tube 10 (23.3)** 24 (22.9)** 7 (7.8)
Antibiotics received in the preceding 3 months
Any antibiotic 42 (93.3)*** 53 (50.5) 42 (46.7)
Penicillins 10 (22.2) 22 (20.2) 21 (23.3)
Cephalosporins 33 (73.3)*** 18 (16.5)* 25 (27.8)
Tetracycline 3 (6.7) 0 0
Aminoglycosides 2 (4.4) 4 (3.7) 2 (2.2)
Macrolides 16 (35.6)*** 4 (3.7) 9 (10.0)
Clindamycin 1 (2.2) 5 (4.6) 5 (5.6)
Quinolones 13 (28.9)*** 7 (6.4) 3 (3.3)
Other 12 (26.7) 13 (11.9) 14 (15.6)
Other drugs received in the preceding 3 months
Proton-pump inhibitors 21 (46.7) 27 (24.8) 31 (34.4)
H2 blockers 2 (4.4) 0 2 (2.2)
Drugs used in diabetes 7 (15.6) 10 (9.2) 11 (12.2)
Antithrombotic agents 30 (66.7)** 55 (50.5) 40 (44.4)
Cardiovascular system, all agents
Digoxin 31 (68.9)* 37 (33.9)* 43 (47.8)
Diuretics 11 (24.4)*** 2 (1.8) 5 (5.6)
b-Blocking agents 18 (40.0) 21 (19.3) 26 (28.9)
Calcium channel 8 (17.8) 17 (15.6) 15 (16.7)
Blockers 8 (17.8) 9 (8.3) 10 (11.1)
Renin–angiotensin 17 (37.8)** 17 (15.6) 17 (18.9)
Modifying agents 7 (15.6) 8 (7.3) 10 (11.1)
Lipid-modifying agents 28 (62.2)** 17 (15.6)** 30 (33.3)
Respiratory medication 17 (37.8) 7 (6.4)*** 22 (24.4)
Immunosuppressive agents, NSAIDs 24 (53.3) 48 (44.0) 43 (47.8)
Data are no. (%) of patients, unless otherwise indicated.
n, number of patients; CDI, Clostridium difﬁcile infection; non-CDI, diarrhoea due
to another cause; NSAIDs, non-steroidal anti-inﬂammatory drugs.
Signiﬁcantly different from control group (*p <0.05, **p <0.01, ***p <0.001).
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previous hospitalization, co-morbidity, and level of care prior
to the development of diarrhoea. Comorbidity was deﬁned
according to the International Classiﬁcation of Disease, ver-
sion 10 (ICD-10). For study groups I and II, the duration of
hospital stay was deﬁned as the number of days from admis-
sion to the development of diarrhoea; for study group III,
it was deﬁned as the number of days from admission to
discharge. Information on the use of antibiotics or other
medication within the preceding 3 months was extracted
from an electronic pharmacy database. This database con-
tained information on all medications prescribed both within
and outside the hospital for every participant in this study.
All medications used were categorized according to the lat-
est international ATC code [28]. The deﬁned daily dose of
antibiotics was established according to the WHO Collabo-
rating Centre for Drug Statistics Methodology guidelines for
ATC classiﬁcation and deﬁned daily dose assignment [28].
For each patient diagnosed with CDI, additional informa-
tion was collected concerning severity of disease, treatment
regimen, disease recurrence, and 30-day mortality. Recurrent
disease was deﬁned as a second episode of diarrhoea within
30 days of diagnosis of CDI following initial clinical improve-
ment, combined with a positive C. difﬁcile toxin assay result
from a stool sample.
Statistical analysis
The distributions of risk factors in study group I and study
group II were compared to the distribution in the control
group (study group III). Continuous data were compared
among groups using analyses of variance. A Yates-corrected
chi-square test was used for the analysis of proportions. If a
cell value was less than ﬁve in the two-by-two table, Fisher’s
exact test was used. A multiple logistic regression model
was used to study the association of putative risk factors
with CDI and non-CDI diarrhoea. Relative risks were
estimated as ORs and presented with a 95% CI. Both crude
ORs and ORs after adjustment for the possible confounder’s
age, duration of hospital stay, comorbidity (ICD-10 cate-
gory), level of care and comedication are presented in
Table 2. All p-values were two-sided. Finally, for both cepha-
losporin therapy and ﬂuoroquinolone therapy, the popula-
tion-attributable risk percentage (PAR%) was calculated as
previously described [29]. All analyses were performed using
SPSS for Windows, version 13.0.
TABLE 2. Crude and adjusted ORs for development of diarrhoea, according to demographic, clinical and pharmaceutical
characteristics
CDI Non-CDI
Crude OR
(95% CI)
Adjusted OR
(95% CI)a
Crude OR
(95% CI)
Adjusted OR
(95% CI)a
Age, years
18–64 1 (reference) 1 1 1
‡65 2.6 (1.0–5.7)* 2.6 (1.0–5.7)* 0.8 (0.5–1.5) 0.8 (0.5–1.5)
Duration of stay in hospital 1.03 (1.0–1.1)* 1.04 (1.0–1.1)* 1.0 (0.9–1.0) 1.0 (0.9–1.0)
Cardiovascular disease 2.7 (1.3–5.6)** 1.9 (0.8–5.2) 1.5 (0.8–2.6) 1.9 (0.9–3.8)
Respiratory system disease 2.3 (1.0–5.2)* 2.7 (0.9–7.9) 0.6 (0.3–1.4) 1.3 (0.5–3.7)
Digestive system disease 1.7 (0.7–4.2) 2.7 (0.9–8.9) 2.2 (1.1–4.5)* 3.1 (1.2–7.8)*
Surgery 0.6 (0.3–1.6) 0.7 (0.2–2.4) 2.2 (1.2–4.1)* 2.1 (1.0–4.3)*
Nasogastric tube 3.4 (1.2–9.5)* 3.6 (1.0–14.3)* 3.3 (1.4–8.1)** 4.8 (1.7–13.6)**
Antibiotics
Any antibiotic 15.3 (4.4–53.2)*** 12.5 (3.2–48.1)*** 1.1 (0.6–2.0) 1.8 (0.9–3.7)
Cephalosporins 7.0 (3.1–15.7)*** 5.7 (1.8–18.6)b,*** 0.5 (0.3–1.0) 0.9 (0.3–2.1)
Macrolides 4.9 (2.0–12.3)*** 2.4 (0.7–8.7)c 0.3 (0.1–1.2) 0.3 (0.1–1.6)
Quinolones 11.6 (3.1–43.6)*** 15.3 (2.7–84.6)d,** 2.0 (0.5–7.8) 2.2 (0.5–10.6)
Other drugs
Proton-pump inhibitors 1.6 (0.8–3.4) 1.1 (0.5–2.6) 0.6 (0.3–1.0)* 0.9 (0.5–1.7)
Antithrombotic agents 2.5 (1.2–5.2)* 1.2 (0.5–2.9) 1.1 (0.7–2.2) 1.7 (0.8–3.6)
Cardiovascular agents, all
Digoxin 2.4 (1.1–5.0)* 1.3 (0.4–4.9) 0.6 (0.3–1.0)* 0.7 (0.4–1.5)
Renin–angiotensin 5.4 (1.8–16.8)** 2.3 (0.6–12.1) 0.3 (0.1–1.7) 0.5 (0.1–3.2)
Modifying agents 2.6 (1.2–5.7)* 2.2 (0.7–7.0) 0.8 (0.4–1.6) 0.9 (0.4–2.2)
Respiratory medication 3.2 (1.5–6.8)** 1.1 (0.4–3.2) 0.4 (0.2–0.7)** 0.6 (0.2–1.2)
Immunosuppressive agents 1.8 (0.9–4.0) 0.9 (0.3–2.5) 0.2 (0.1–0.5)** 0.4 (0.1–1.0)*
NSAIDs 1.2 (0.6–2.5) 1.0 (0.4–2.4) 0.8 (0.5–1.5) 1.0 (0.5–1.9)
CDI, Clostridium difﬁcile infection; non-CDI, diarrhoea due to another cause.
aAdjusted for differences in age, duration of hospital stay, comorbidity (ICD-10), level of care, and comedication.
bAdditional adjustment for concomitant use of macrolides and quinolones.
cAdditional adjustment for concomitant use of cephalosporins and quinolones.
dAdditional adjustment for concomitant use of cephalosporins and macrolides.
*p <0.05; **p <0.01; ***p <0.001.
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Results
Description of the outbreak
The background incidence of CDI in St Jansdal Hospital was
3.8 patients per 10 000 admissions in 2004. In 2005, a more
than ten-fold increase in the incidence of CDI was observed
(Fig. 1). In this study, we included the ﬁrst 45 patients diag-
nosed with CDI in 2005. In total, 50 patients with CDI were
diagnosed during the outbreak. Faeces were cultured, and
C. difﬁcile isolates were identiﬁed as toxinotype III and PCR
ribotype 027. In addition, the strain had the binary toxin
genes and contained an 18-bp deletion in the toxin regulator
gene tcdC. The isolates were resistant to erythromycin
(MIC >256 mg/L) and ciproﬂoxacin (MIC >32 mg/L), and
susceptible to clindamycin (MIC 2 ml/L) and metronidazole
(MIC 0.19 mg/L).
A multidisciplinary hospital outbreak management team
(OMT) was formed to coordinate measures to control the
epidemic. Special folders informed medical personnel in the
hospital. In addition, all clinicians were informed personally.
The medical microbiologist and infection control practitioner
organized special meetings on the involved wards with the
nursing staff. The cleaning team received special instructions
for intensiﬁed cleaning procedures from the infection control
practitioner. All measures were described in a CDI hospital
guideline by the OMT.
Measures taken by the OMT to control the epidemic
(from 1 May 2005 onwards) included isolation of all patients
with diarrhoea (until two tests, 24 h apart, gave negative
results for C. difﬁcile toxin), hand washing with water and
soap, use of chlorine-containing disinfectant (0.1% sodium
hypochlorite), and cohorting of all C. difﬁcile-infected patients
on a separate ward. In addition, from 7 July 2005 until 14
September 2005, a complete ban on all ﬂuoroquinolones was
established, and the use of cephalosporins and clindamycin
was limited.
The course of the epidemic, including the time-scheme of
all infection control measures taken and the use of antibiot-
ics in the hospital, are depicted in Fig. 1. The outbreak came
to an end in September 2005. After the re-introduction of
ﬂuoroquinolones, however, a temporary increase in CDI was
noticed.
Description of C. difﬁcile-associated disease cases
From 1 April 2005 until the end of August 2005, a total of
45 patients met the case deﬁnition of CDI. Clinical charac-
teristics of the CDI cases are given in Table 1. Thirty-ﬁve
patients developed diarrhoea during their stay in the hospital
(mean duration of hospital stay prior to development of
symptoms was 13 days). Of the ten patients admitted with
diarrhoea, nine patients had healthcare-associated CDI, as
they had been hospitalized in the same hospital within the
preceding 3 months. The only patient who had not been
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hospitalized before was suffering from ulcerative colitis and
was known to have frequent periods of diarrhoea.
The symptoms and signs most frequently observed within
the ﬁrst 2 weeks following onset of diarrhoea were fever
(53.3%), abdominal pain (20%), high white blood cell count in
the ﬁrst 2 weeks after onset of diarrhoea (mean
1.6 · 1010 cells/mL; >2.0 · 1010 cells/mL in 23.7% of cases),
high erythrocyte sedimentation rate (mean, 48.2 mm/h), high
serum creatinine level (mean, 0.149 mmol/L; >0.200 mmol/L
in 17.5% of cases), and low serum albumin level (mean,
28.6 g/L). Bloody stools were noticed in only three patients
(6.7%). All but two patients were treated with vancomycin
or metronidazole or a combination of both. Recurrence of
diarrhoea following initial improvement was observed in ten
patients (22%). In nine of these patients, a positive C. difﬁcile
toxin assay result was obtained from a stool sample. Recur-
rence of CDI was more often seen in patients with a peak
white blood cell count >2.0 · 1010 cells/mL (p 0.002; OR 16,
and 95% CI 2.8–90.4) or a peak serum creatinine level
>0.200 mmol/L (p 0.03; OR 7.1, and 95% CI 1.3–40.2). Nine
patients (20%) with CDI died within 30 days after diagnosis,
three (7%) as a direct result of CDI. A peak white blood cell
count >2.0 · 1010 cells/mL within the ﬁrst 2 weeks following
onset of diarrhoea was a strong predictor of mortality
(p 0.01; OR 7.8, and 95% CI 1.5–39.1).
Case–control study
Table 1 presents the characteristics of the participants in the
case–control study. Table 2 shows the risk of CDI and
non-CDI diarrhoea. Both crude ORs (univariate analysis) and
adjusted ORs (multivariate analysis) are given (only charac-
teristics that were signiﬁcantly different among study groups
in the univariate analysis are shown). After adjustment for
differences in comorbidity, level of care, and comedication,
the independent risk factors for CDI were age above
65 years (OR 2.6), duration of hospitalization (OR 1.04 per
additional day), and antibiotic use (OR 12.5). Independent
risk factors for non-CDI diarrhoea were underlying digestive
system disease (OR 3.1) and previous surgery (OR 2.1).
Although immunosuppressive agents and proton-pump inhibi-
tors were not associated with CDI, patients with non-CDI
diarrhoea were less often treated with these. Finally, naso-
gastric tube feeding appeared to be a general risk factor for
diarrhoea, being associated both with CDI (OR 3.6) and with
non-CDI diarrhoea (OR 4.8).
Antibiotic use was exclusively associated with CDI. Of all
antibiotics, cephalosporins, macrolides and ﬂuoroquinolones
were associated with CDI in the univariate analysis (Table 2).
After correction for differences in comorbidity, level of care,
co-medication, and the use of multiple antibiotics, the associ-
ation of CDI with macrolides was no longer signiﬁcant. Even
with the small numbers in our study, we could demonstrate
a statistically signiﬁcant interaction between cephalosporin
and ﬂuoroquinolone use in the multivariate analysis (OR for
the interaction factor, 13.6; p 0.006). To study this interac-
tion in more detail, we analysed the risk of CDI for different
treatment schemes (Fig. 2). In this analysis, cephalosporin
monotherapy (OR 7.8, 95% CI 2.9–20.9) and ﬂuoroquino-
lone monotherapy (OR 28.8, 95% CI 2.6–319.2) were
shown to be independent risk factors for CDI. Patients who
used a combination of both antibiotics in the preceding
3 months had the highest risk of developing CDI (OR 57.5,
95% CI 6.8–483.6). The PAR%, i.e. the proportion of CDI
cases in the study population that was attributable to the
use of cephalosporin or ﬂuoroquinolone therapy, was calcu-
lated as 56% and 33%, respectively.
Discussion
In 2005, the ﬁrst outbreak of CDI due to C. difﬁcile 027/III/
NAP1/BI occurred in a medium-size hospital in The Nether-
lands. As was also observed during the recent epidemics in
Europe and North America, the outbreak was very difﬁcult to
control, and came to an end only after implementation of
measures in addition to general measures of hygiene, i.e.
cohorting of all C. difﬁcile-infected patients on a separate ward,
education of staff, intensiﬁed cleaning of the environment, and
strong limitations on antibiotic use. These measures have also
been described as an effective comprehensive ‘bundle’
approach to combat CDI oubreaks in the USA [30,31].
The use of cephalosporins is a well-documented risk
factor for the development of CDI [15–17]. In this study, ﬂu-
oroquinolone therapy, especially in combination with cepha-
losporin therapy, was identiﬁed as another major risk factor
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for the development of CDI. Ciproﬂoxacin is still the main
ﬂuoroquinolone used in The Netherlands. In our study popu-
lation, 22 patients used ciproﬂoxacin and only one patient
used moxiﬂoxacin. Although ﬂuoroquinolones account only
for a small proportion of all antibiotics used in St Jansdal
Hospital (9.5% of all antibiotics prescribed, in contrast to
31% for cephalosporins), the proportion of CDI cases in the
study population that was attributable to the use of ﬂuor-
oquinolones was as high as 33%. This ﬁnding is in line with
results reported by Pepin et al. [23], who calculated a PAR%
of 35.9% for ﬂuoroquinolones during a large outbreak of
nosocomial CDI in Canada.
Associations between CDI and ﬂuoroquinolones, including
ciproﬂoxacin, have been described previously [23–25,32–36].
A recent study, which included ‘CDAD pressure’ as a risk
factor for the development of CDI, found ciproﬂoxacin to
be an independent factor [14]. In The Netherlands, cipro-
ﬂoxacin has been recognized as a risk factor for acquisition
of CDI, particularly infection due to PCR ribotype type 027
[12]. However, the exact role of ﬂuoroquinolones in the
aetiology of CDI is still unclear. An important factor might
be the increasing ﬂuoroquinolone resistance of C. difﬁcile,
which has been observed worldwide [37,38], coupled with
an increasing use of ﬂuoroquinolones, leading to more efﬁ-
cient proliferation of resistant clones following disruption of
colonic ﬂora. Until 2000, no relationship between CDI and
the use of ciproﬂoxacin and oﬂoxacin had been reported.
Interestingly, two historical isolates of C. difﬁcile from 1987,
which were also typed as 027/III/NAP1/BI, were susceptible
to ﬂuoroquinolones [6]. Therefore, we consider it very likely
that the acquisition of ﬂuoroquinolone resistance contributed
to the increased spread of this hypervirulent strain. Recently,
several authors have underlined the importance of the
improved anti-anaerobe spectrum of the newer ﬂuoroquinol-
ones in the aetiology of CDI [25,37]. However, this does
not apply to ciproﬂoxacin, which possesses poor in vitro
activity against anaerobic bacteria.
As correctly stated by Wilcox et al. [1], the duration of
treatment and antibiotic polypharmacy affect the incidence of
CDI, and may confound risk analyses for antimicrobial agents.
Pepin et al. [23] suggested that long duration of ﬂuoroquino-
lone therapy, in particular, enhances the risk of CDI. Unfortu-
nately, we did not have sufﬁcient data to assess the possible
effect of duration of treatment on the risk of CDI in our
study. With respect to polypharmacy, it must be noted that,
in The Netherlands, ﬂuoroquinolones are often administered
together with cephalosporins, e.g. in empirical therapy of
severe community-acquired pneumonia. In a separate analysis,
after correcting for differences in comedication and the use
of multiple antibiotics, we could demonstrate that patients
who had received ﬂuoroquinolone monotherapy within
the preceding 3 months were also at very high risk of devel-
oping CDI. This clearly demonstrates that ﬂuoroquinolones
represent an independent risk factor for C. difﬁcile-associated
disease in our population. Surprisingly, the risk of developing
CDI was extremely high in people receiving a combination of
cephalosporins and ﬂuoroquinolones. The fact that the OR in
these subjects was much higher (57.5) than could be
explained by simply summing the ORs for the separate antibi-
otics (7.8 and 28.8, respectively) could suggest a synergistic
effect of cephalosporins and ﬂuoroquinolones in the aetiology
of CDI.
In addition to antibiotic use, several other risk factors
have been associated with the development of CDI [15–25].
Analysing three different study populations, we were able to
demonstrate that underlying digestive system disease,
previous surgery and gastric tube feeding are not speciﬁcally
associated with CDI, but are general risk factors for (non-
infectious) diarrhoea. In addition, we demonstrated that
although proton-pump inhibitors and immunosuppressive
medication were not associated with CDI, subjects with
non-infectious diarrhoea less frequently used these drugs.
This observation indicates that differences in selection of
control subjects may underlie the inconsistency among
studies regarding the role of proton-pump inhibitors and
immunosuppressive medication in the aetiology of CDI.
Unfortunately, we were unable to determine the role of
‘CDI pressure’ as a risk factor [13,14].
Most experts emphasize that antimicrobial intervention
alone is unlikely to result in successful control of all CDI
outbreaks. Issues related to the environment, education and
infection control should also be addressed [30] A recently
published ECDC-supported guideline emphasizes the
importance of antimicrobial stewardship in conjunction with
proper environmental disinfection, hand hygiene compliance,
protective clothing, education of staff, and single-room isola-
tion or cohorting of CDI patients [39]. The outbreak
described here ended only after the formation of a multidisci-
plinary hospital OMT to coordinate measures to control the
epidemic, the enhancement of case-ﬁnding and compliance by
continuous education, isolation of all patients with diarrhoea
until CDI was excluded, increasing the rapidity of microbio-
logical diagnosis by using repeated stool ICTAB testing, the
implementation of speciﬁc hygiene measures (including hand
washing with water and soap and intensiﬁed environmental
cleaning procedures), the cohorting of all CDI patients on a
separate ward, and the implementation of an antimicrobial
stewardship programme. The value of implementation of a
CDI control ‘bundle’, including early identiﬁcation, coupled
with appropriate control measures, in reducing the rate of
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CDI and the frequency of adverse events in a university hos-
pital was shown recently by Muto et al. [31]. The importance
of appropriate antimicrobial stewardship has recently been
illustrated by a report from Canada. Valiquette et al. [40]
reported that no change in CDI incidence was noted after
strengthening of infection control procedures, but that
implementation of the antimicrobial stewardship programme
was followed by a marked reduction in incidence. These
observations are very similar to those made in this study, as
an effective outbreak control was only obtained after strong
restrictions on the use of cephalosporins and a complete ban
on the use of ciproﬂoxacin. The decline in CDI cases follow-
ing restriction of cephalosporin use and a complete ban on
the use of ﬂuoroquinolones in our hospital, followed by an
increase in CDI cases following the reintroduction of
ﬂuoroquinolones, underline the importance of these antibiot-
ics in the development of CDI.
In conclusion, cephalosporin therapy and ﬂuoroquinolone
therapy were identiﬁed as important risk factors for the devel-
opment of CDI during an outbreak of C. difﬁcile PCR ribotype
027 in The Netherlands. The risk of developing CDI was partic-
ularly high in people receiving a combination of cephalosporins
and ﬂuoroquinolones. Our data indicate the importance of
good antimicrobial stewardship, in relation with other
measures, to control outbreaks of C. difﬁcile PCR ribotype 027.
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